Navigation Links
Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
Date:11/14/2013

THOUSAND OAKS, Calif., Nov. 14, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2013 on Tuesday, Nov. 19, at 7 p.m. CST. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.

Live audio of the investor meeting will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patien
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/14/2014)... been made in chemotherapy over the past decade, but ... continues to be a major challenge. , Nanotechnology ... the use of nanocarriers, or capsules, that can transport ... body. , The catch? These carriers are tiny, and ...
(Date:4/14/2014)... the 20th century, is currently losing a lot of ... at the University of South Carolina have just reported ... against so-called "superbugs." , Bacteria have been chipping away ... since their first wide-scale use as antibiotics in the ...
(Date:4/14/2014)... web information on colorectal cancer is too difficult for ... appropriate risks to and concerns of patients, a study ... a review of a dozen popular websites, most of ... were written beyond the recommended sixth-grade reading level, while ...
(Date:4/14/2014)... Inc., announced today a publication demonstrating that the company,s ... cells exposed to plasma samples of patients with a ... "TNT003, an inhibitor of the serine protease C1s, prevents ... was published on-line in the journal Blood ...
(Date:4/14/2014)... Child Development Institute have released their new study of ... success in kindergarten. According to FPG,s report, students enrolled ... of learning. , "Children are progressing at an ... than expected for normal developmental growth," said senior scientist ...
Breaking Medicine News(10 mins):Health News:Nano shake-up 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Study gives high marks to NC Pre-K program 2
... Skin cancer is the most common form of cancer and nearly ... to the skin. What is all the more alarming is that ... of sunburn & skin cancer admit they still get sunburnt despite ... ,Chronic exposure to sunlight is the cause of nearly ...
... obesity and people who are overweight, may not be ... systematically reviewed the current evidence for the supplement had ... Cochrane Library.// ,The review assessed results ... or obese adults. Those who received chitosan had an ...
... the people in South India wake up to the lovely ... celebrate for these coffee lovers now, with firm evidence from ... a morning jolt and has been found to contain substances ... Antioxidants in general have been linked to a number of ...
... common cancer diagnosed in men and the risk of ... the best form of therapy for prostate cancer remains ... options are available to patients: traditional open surgery, laparoscopic ... surgery. ,Prostate cancer patients biggest concerns following ...
... women who try to lose weight apparently have to choose ... weight loss , the supermodel Rachel Hunter has criticized "Desperate ... loss. , ,Hunter said that Hatcher's face looked older ... was once married to rocker Rod Stewart, went on to ...
... 28 : Researchers report that mother to be who ... on the growth of their unborn babies., ,Researchers ... adverse pregnancy outcomes // - primary caesarean delivery, pre-term ... group., ,Terry J. Rosenberg of Medical Health and ...
Cached Medicine News:Health News:Benefits Of Robotic Prostate Surgery- But At What Cost? 2Health News:Hollywood Actress Hunter criticises Hatcher for weight loss. 2Health News:Obesity, diabetes in pregnant women affects babies 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: